Why Can't Anyone Stop Compounded GLP-1s?

Because federal, legal, and private forces won't allow it

Nov 2 • 

Ashwin Sharma, MD

23

3

September 2025

What Comes After the GLP-1 Hype?

It's messy, unglamorous stuff involving patients and insurers and crystal balls for pharma

Sep 28 • 

Ashwin Sharma, MD

20

5

When GLP-1s become brain drugs

Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?

Sep 14 • 

Ashwin Sharma, MD

28

3

Why Novo Nordisk and Eli Lilly Won't Compete on Price

But they will compete on market access and launch success

Sep 1 • 

Ashwin Sharma, MD

20

5

August 2025

The $100 Billion Overreaction

how do oral GLP-1s expand the market?

Aug 24 • 

Ashwin Sharma, MD

17

Why Britain’s GLP-1 Patients Are Paying for America’s Drug Politics

1.5 million become collateral damage

Aug 17 • 

Ashwin Sharma, MD

12

3

Why Novo Nordisk is Out of Options (Except One)

patents become weapons

Aug 5 • 

Ashwin Sharma, MD

37

23

July 2025

Are GLP-1s About to Kill the Alcohol Industry?

Change is definitely coming, but not in the way you think

Jul 13 • 

Ashwin Sharma, MD

14

GLP-1s Are Quietly Killing Your Cravings (and Maybe Your Bad Habits Too)

New brain-imaging studies reveal these meds may silence the impulse engine driving addiction, compulsive behaviours, and billion-dollar snack aisles

Jul 6 • 

Ashwin Sharma, MD

96

8

June 2025

Hims Has No Way Out of Their $725 Million Hole

Compounding's banned. No branded alternatives. Patent reality bites.

Jun 29 • 

Ashwin Sharma, MD

6

2

How GLP-1s Are Breaking Life Insurance

Patients look healthy on paper. Two years later, they're high-risk again.

Jun 22 • 

Ashwin Sharma, MD

196

33

Why Novo Nordisk Won't Beat Eli Lilly

Dividends over R&D is not a good strategy

Jun 15 • 

Ashwin Sharma, MD

8